[go: up one dir, main page]

PE20081315A1 - Derivados de benzimidazol como antagonistas de vr-1 - Google Patents

Derivados de benzimidazol como antagonistas de vr-1

Info

Publication number
PE20081315A1
PE20081315A1 PE2007001076A PE2007001076A PE20081315A1 PE 20081315 A1 PE20081315 A1 PE 20081315A1 PE 2007001076 A PE2007001076 A PE 2007001076A PE 2007001076 A PE2007001076 A PE 2007001076A PE 20081315 A1 PE20081315 A1 PE 20081315A1
Authority
PE
Peru
Prior art keywords
ethyl
halogen
methyl
antagonists
benzimidazole derivatives
Prior art date
Application number
PE2007001076A
Other languages
English (en)
Inventor
William L Brown
Shawn Johnstone
Denis Labrecque
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081315A1 publication Critical patent/PE20081315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZIMIDAZOL DE FORMULA (I) DONDE R1 ES CN, HALOGENO, C(=)CH3; R2 ES METILO O H; R3 ES H O HALOGENO, R4 Y R5 SON INDEPENDIENTEMENTE METILO O ETILO, O JUNTOS AL ATOMO C AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO DE 3 A 6 MIEMBROS O HETEROCICLO DE 5 A 6 MIEMBROS; R6 Y R7 SON INDEPENDIENTEMENTE H, HALOGENO, METILO O ETILO. SON SELECCIONADOS: (S)(-)-2-(7-CIANO-1H-BENZIMIDAZOL-1-IL)-N-{1-[4-(1-CIANO-1-METILETIL)FENIL]ETIL}ACETAMIDA, (S)(-)-N-{1-[4-(1-CIANO-1-METILETIL)FENIL]ETIL}-2-(7-FLUORO-1H-BENZIMIDAZOL-1-IL)ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE VR1 (RECEPTOR VANILLOIDE 1) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR
PE2007001076A 2006-08-11 2007-08-10 Derivados de benzimidazol como antagonistas de vr-1 PE20081315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83724906P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
PE20081315A1 true PE20081315A1 (es) 2008-11-08

Family

ID=39033277

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001076A PE20081315A1 (es) 2006-08-11 2007-08-10 Derivados de benzimidazol como antagonistas de vr-1

Country Status (25)

Country Link
US (2) US7906654B2 (es)
EP (1) EP2051967B1 (es)
JP (1) JP5140077B2 (es)
KR (1) KR101412881B1 (es)
CN (2) CN101792436A (es)
AR (1) AR062299A1 (es)
AU (1) AU2007282186B2 (es)
BR (1) BRPI0715746B8 (es)
CA (1) CA2660529C (es)
CL (1) CL2007002343A1 (es)
CO (1) CO6150176A2 (es)
ES (1) ES2533971T3 (es)
IL (1) IL196672A0 (es)
MX (1) MX2009001496A (es)
MY (1) MY147649A (es)
NO (1) NO20091054L (es)
NZ (1) NZ575416A (es)
PE (1) PE20081315A1 (es)
RU (1) RU2458055C2 (es)
SG (1) SG173360A1 (es)
TW (1) TWI433839B (es)
UA (1) UA96764C2 (es)
UY (1) UY30533A1 (es)
WO (1) WO2008018827A1 (es)
ZA (1) ZA200900961B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8362012B2 (en) 2008-04-18 2013-01-29 Daewoong Pharmaceutical Co., Ltd. Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
JP6215324B2 (ja) 2012-07-18 2017-10-18 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US10227487B2 (en) 2014-12-08 2019-03-12 Rohm And Haas Company Polyolefin additive, a sag resistant polyolefin and a method of preparing the same
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
KR20210148081A (ko) * 2019-01-08 2021-12-07 네오메드 인스티튜트 (s)-2-(7-시아노-1h-벤즈이미다졸-1 일)-n-(1-(4-(1-시아노-1-메틸에틸)페닐)에틸)아세트아미드의 결정 형태
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN117623972A (zh) * 2022-08-17 2024-03-01 上海慧聚药业有限公司 非离子型造影剂中间体的合成

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
BE793718A (fr) 1972-01-07 1973-07-05 Merck & Co Inc Aminobenzimidazoles
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4738981A (en) * 1984-11-13 1988-04-19 Warner-Lambert Substituted trans-1,2-diaminocyclohexyl amide compounds
JP2639000B2 (ja) 1988-09-30 1997-08-06 スズキ株式会社 酸素富化エンジンの酸素富化空気制御装置
JPH0295767A (ja) 1988-09-30 1990-04-06 Showa Alum Corp 吸気マニホルド
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6166219A (en) 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
HK1046866A1 (zh) 1999-08-12 2003-01-30 法玛西雅意大利公司 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
HK1050008A1 (zh) 2000-05-05 2003-06-06 Portola Pharmaceuticals, Inc. 杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂
EP1294718A2 (en) 2000-06-14 2003-03-26 Warner-Lambert Company Llc 6,5-fused bicyclic heterocycles
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1312601A4 (en) 2000-08-22 2005-09-21 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
ITTO20010110A1 (it) 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
MXPA03011083A (es) 2001-06-11 2004-07-08 Biovitrum Ab Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii.
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
JP2005501873A (ja) 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
JP4059473B2 (ja) 2001-08-09 2008-03-12 株式会社ルネサステクノロジ メモリカード及びメモリコントローラ
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
NZ552282A (en) 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
FR2842069B1 (fr) 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
WO2004035549A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
SE0402284D0 (sv) 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Also Published As

Publication number Publication date
EP2051967A4 (en) 2011-06-29
BRPI0715746B8 (pt) 2021-05-25
RU2009103675A (ru) 2010-09-20
CN101522637A (zh) 2009-09-02
ES2533971T3 (es) 2015-04-16
CO6150176A2 (es) 2010-04-20
UA96764C2 (ru) 2011-12-12
EP2051967B1 (en) 2014-12-31
EP2051967A1 (en) 2009-04-29
IL196672A0 (en) 2009-11-18
CA2660529A1 (en) 2008-02-14
AU2007282186B2 (en) 2011-07-07
UY30533A1 (es) 2008-03-31
NZ575416A (en) 2011-10-28
MX2009001496A (es) 2009-02-18
CL2007002343A1 (es) 2008-04-04
BRPI0715746A2 (pt) 2013-07-16
US7906654B2 (en) 2011-03-15
JP5140077B2 (ja) 2013-02-06
CN101792436A (zh) 2010-08-04
AR062299A1 (es) 2008-10-29
CA2660529C (en) 2014-10-21
US8093402B2 (en) 2012-01-10
US20110137045A1 (en) 2011-06-09
JP2010500345A (ja) 2010-01-07
US20080221188A1 (en) 2008-09-11
AU2007282186A1 (en) 2008-02-14
KR101412881B1 (ko) 2014-06-26
NO20091054L (no) 2009-03-09
TW200817338A (en) 2008-04-16
RU2458055C2 (ru) 2012-08-10
SG173360A1 (en) 2011-08-29
WO2008018827A1 (en) 2008-02-14
WO2008018827A8 (en) 2009-02-19
TWI433839B (zh) 2014-04-11
BRPI0715746B1 (pt) 2020-09-24
MY147649A (en) 2012-12-31
KR20090035701A (ko) 2009-04-10
ZA200900961B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20131377A1 (es) Triazina-oxadiazoles
PE20141681A1 (es) Inhibidores de btk
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
AR072189A1 (es) Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio.
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed